LPAR1

LPAR1

A gene on chromosome 9q31.3 that encodes an endothelial differentiation, G protein-coupled (EDG) family receptor for lysophosphatidic acid, a bioactive lysophospholipid that mediates diverse biologic functions, including proliferation, platelet aggregation, smooth
muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis and tumour cell invasion.
References in periodicals archive ?
Global Markets Direct's, 'Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) - Pipeline Review, H1 2016', provides in depth analysis on Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1) targeted pipeline therapeutics.
The report provides comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg-2 or LPAR1 or EDG2 or LPA1)
Based on the hypothesis of steroid dependency of the proliferation-stimulating LPAR, the researchers assessed the expressions of LPAR1 to LPAR6 in the presence of AA by propagating prostate cancer cell lines, namely PC-3 (highly metastatic) and LNCaP (low metastatic potential).
AA treatment was also verified to also target proliferative factors LPAR1, LPAR3, LPAR4, LPAR5 and LPAR6.